Interstitial Granulomatous Drug Reaction to SorafenibMARTINEZ-MORAN, Cristina; NAJERA, Laura; RUIZ-CASADO, Ana I et al.Archives of dermatology (1960). 2011, Vol 147, Num 9, pp 1118-1119, issn 0003-987X, 2 p.Article

Hand-foot and stump syndrome to sorafenibLAI, Susan E; KUZEL, Timothy; LACOUTURE, Mario E et al.Journal of clinical oncology. 2007, Vol 25, Num 3, pp 341-342, issn 0732-183X, 2 p.Article

Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiationPLASTARAS, John P; KIM, Seok-Hyun; DIEHL, J. Alan et al.Cancer research (Baltimore). 2007, Vol 67, Num 19, pp 9443-9454, issn 0008-5472, 12 p.Article

Sorafenib-Associated Psoriasiform Skin ChangesLAQUER, Vivian; SAEDI, Nazanin; DANN, Frank et al.Cutis (New York, NY). 2010, Vol 85, Num 6, pp 301-302, issn 0011-4162, 2 p.Article

Meta-analysis of dermatological toxicities associated with sorafenibZHANG, L; ZHOU, Q; MA, L et al.Clinical and experimental dermatology (Print). 2011, Vol 36, Num 4, pp 344-350, issn 0307-6938, 7 p.Article

Cutaneous Drug Eruptions Induced By Sorafenib : A Case SeriesMADDOX, Jessica S; KUNG, Elaine F; PETRONIC-ROSIC, Vesna et al.Journal of drugs in dermatology. 2008, Vol 7, Num 9, pp 891-893, issn 1545-9616, 3 p.Article

Atypical linear toxicodermia by sorafenibRODRIGUEZ-VAZQUEZ, Maria; GARCIA-ARPA, Mónica; INIGUEZ DE ONZONO, Luis et al.RODRIGUEZ-VAZQUEZ, Maria; International journal of dermatology. 2010, Vol 49, Num 10, pp 1214-1215, issn 0011-9059, 2 p.Article

The histologic spectrum of epithelial neoplasms induced by sorafenibEUN JI KWON; KISH, L. Stephen; JAWORSKY, Christine et al.Journal of the American Academy of Dermatology. 2009, Vol 61, Num 3, pp 522-527, issn 0190-9622, 6 p.Article

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibLEE, W. J; LEE, J. L; CHANG, S. E et al.British journal of dermatology (1951). 2009, Vol 161, Num 5, pp 1045-1051, issn 0007-0963, 7 p.Article

Naevus éruptifs sous sorafénib = Eruptive naevi associated with sorafenib treatmentBENNANI-LAHLOU, M; MATEUS, C; ESCUDIER, B et al.Annales de dermatologie et de vénéréologie. 2008, Vol 135, Num 10, pp 672-674, issn 0151-9638, 3 p.Article

Kératoacanthomes multiples éruptifs induits par le sorafénib = Sorafenib-induced multiple eruptive keratoacanthomasJANTZEM, H; DUPRE-GOETGHEBEUR, D; SPINDLER, P et al.Annales de dermatologie et de vénéréologie. 2009, Vol 136, Num 12, pp 894-897, issn 0151-9638, 4 p.Article

Sorafenib exerts anti-glioma activity in vitro and in vivoSIEGELIN, Markus D; RASKETT, Christopher M; GILBERT, Candace A et al.Neuroscience letters. 2010, Vol 478, Num 3, pp 165-170, issn 0304-3940, 6 p.Article

Dermatologic symptoms associated with the multikinase inhibitor sorafenibROBERT, Caroline; MATEUS, Christina; SPATZ, Alain et al.Journal of the American Academy of Dermatology. 2009, Vol 60, Num 2, pp 299-305, issn 0190-9622, 7 p.Article

Acute pancreatitis associated with sorafenibMINGQING LI; SRINIVAS, Sandy.Southern medical journal (Birmingham). 2007, Vol 100, Num 9, pp 909-911, issn 0038-4348, 3 p.Article

Sorafenib use while waiting for liver transplant: We still need to waitFINN, Richard S.Journal of hepatology. 2012, Vol 56, Num 3, pp 723-725, issn 0168-8278, 3 p.Article

Sorafenib-induced erythema multiforme: three casesNAMBA, Mio; TSUNEMI, Yuichiro; KAWASHIMA, Makoto et al.EJD. European journal of dermatology. 2011, Vol 21, Num 6, pp 1015-1016, issn 1167-1122, 2 p.Article

Drug Therapy: SorafenibFINN, Richard S.Hepatology (Baltimore, Md.). 2010, Vol 51, Num 5, pp 1843-1849, issn 0270-9139, 7 p.Article

Erythema marginatum hemorrhagicum: A unique cutaneous side effect of sorafenibRIIBSAM, Katharina; FLAIG, Michael J; RUZICKA, Thomas et al.Journal of the American Academy of Dermatology. 2011, Vol 64, Num 6, pp 1194-1196, issn 0190-9622, 3 p.Article

Sorafenib-induced eruption resembling pityriasis rubra pilarisPAZ, Carlos; QUERFELD, Christiane; SHEA, Christopher R et al.Journal of the American Academy of Dermatology. 2011, Vol 65, Num 2, pp 452-453, issn 0190-9622, 2 p.Article

Sorafenib: Where Do We Go from Here?SIEGEL, Abby B; OLSEN, Sonja K; MAGUN, Arthur et al.Hepatology (Baltimore, Md.). 2010, Vol 52, Num 1, pp 360-369, issn 0270-9139, 10 p.Article

Non-pigmenting Fixed Drug Eruption Induced by SorafenibTANABE, Kenichi; AMOH, Yasuyuki; MII, Sumiyuki et al.Acta dermato-venereologica. 2010, Vol 90, Num 3, issn 0001-5555, p. 307Article

Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppressionTAKEUCHI, Ario; SHIOTA, Masaki; TATSUGAMI, Katsunori et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1557-1564, issn 0344-5704, 8 p.Article

Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib : Neue kutane Arzneimittelnebenwirkunger = Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib : New cutaneous side effects of drugsWOLLENBERG, A; STAEHLER, M; EAMES, T et al.Der Hautarzt. 2010, Vol 61, Num 8, pp 662-667, issn 0017-8470, 6 p.Article

Diferentes alteraciones genéticas causan diferentes melanomas y nuevas posibilidades terapéuticas = New Therapies Targeting the Genetic Mutations Responsible for Different Types of MelanomaBOTELLA-ESTRADA, R; SANMARTIN JIMENEZ, O.Actas dermo-sifiliográficas (Ed. impresa). 2010, Vol 101, Num 5, pp 394-400, issn 0001-7310, 7 p.Article

Antitumor activity of sorafenib in FLT3-driven leukemic cellsAUCLAIR, D; MILLER, D; ROCKS, S et al.Leukemia. 2007, Vol 21, Num 3, pp 439-445, issn 0887-6924, 7 p.Article